Cassava Sciences, Inc.

SAVA

17 Followers

$1.51

-5.63%

-$0.09

9 May

Upcoming Earnings

Market Cap.

P/E

Overview Metrics Financials

SAVA Fair Price

$6.36

Overvalued by 30.4%

To display the fair price of a share, you need to be a member of Bulios Black.

My Notes

Začít psát

Profile

Cassava Sciences, Inc. (SAVA) is a biotechnology company focused on research and development of therapeutic treatments for neurodegenerative diseases. The company's primary goal is to discover innovative therapies targeting Alzheimer's disease, one of the most devastating cognitive impairing illnesses. Cassava Sciences is developing a drug known as Simufilam, which has undergone clinical trials and has shown promising results in improving cognitive functions in Alzheimer's disease patients. Investing in Cassava Sciences' stock may present an attractive opportunity for investors who closely follow advancements in neurodegenerative disease treatments and seek innovative companies with potential in the biotechnology field.